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I. INTRODUCTION 
In 1999, nine years after the National Institutes of Health’s 
(“NIH”) National Center for Human Genome Research had published 
its first joint research plan, the project to sequence the human genome 
was operating at full force.1 The entire genome of a free-living organ-
ism, Haemophilus influenzae, had already been sequenced,2 and the 
first full human chromosome sequence would be published that same 
year.3 The joint announcement by President Bill Clinton and United 
Kingdom Prime Minister Tony Blair of the so-called rough draft hu-
man genome would be made the following year.4 
This burgeoning body of genomic knowledge required analytical 
tools for parsing and manipulating it productively. Though such tools 
had long existed in computer science and had even been applied to 
research problems in the life sciences under the designation of bioin-
formatics, they had not yet been systematized into a formal disci-
pline.5 The specialization of such tools to manage the peculiar scope 
and scale of genomic information marked the origin of bioinformatics 
as a distinct discipline.6 
Perhaps not surprisingly, the United States Patent and Trademark 
Office (“USPTO”) had begun receiving a growing number of patent 
applications for inventions in the field of bioinformatics.7 Based on 
industry input, it projected many more in the coming years.8 In re-
                                                                                                                  
1. A Brief History of the Human Genome Project, NIH NATIONAL HUMAN GENOME 
RESEARCH INSTITUTE (Nov. 8, 2012), http://www.genome.gov/12011239 
[http://perma.cc/B6GW-5X7G]. 
2. Robert D. Fleischmann et al., Whole-Genome Random Sequencing and Assembly of 
Haemophilus Influenzae Rd, 269 SCIENCE 496, 496 (1995). 
3. Ian Dunham et al., The DNA Sequence of Human Chromosome 22, 402 NATURE 489, 
489 (1999). 
4. Press Release, The White House Office of the Press Secretary, President Clinton An-
nounces the Completion of the First Survey of the Entire Human Genome: Hails Public and 
Private Efforts Leading to This Historic Achievement (June 26, 2000), 
http://archive.hhs.gov/news/press/2000pres/20000626.html [http://perma.cc/T2XQ-L8RH]. 
5. In 2000, NIH issued a working definition of bioinformatics which accounted for the 
utility of the field in the expansive use of available biological information. See NIH Working 
Definition of Bioinformatics and Computational Biology, NIH BIOMEDICAL INFORMATION 
SCIENCE AND TECHNOLOGY INITIATIVE (July 17, 2000), 
http://www.bisti.nih.gov/docs/CompuBioDef.pdf [http://perma.cc/RKW9-5G2J]. 
6. Jorge L. Contreras, Implementing Procedural Safeguards for the Development of Bio-
informatics Interoperability Standards, 39 N. KY. L. REV. 87, 87 (2012). 
7. Douglas Steinberg, New PTO Unit Examines Bioinformatics Applications, THE 
SCIENTIST (Nov. 27, 2000), http://www.the-scientist.com/?articles.view/articleNo/13144/ 
[https://perma.cc/C66V-FJHP]. 
8. Id. 
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sponse, by December of 1999, the USPTO had established a new art 
unit to examine all bioinformatics applications in a consistent way.9 
The art unit resides in USPTO Technology Center 1600,10 which ex-
amines inventions in biotechnology and organic chemistry11 and is 
designated art unit (“AU”) 1631.12 
From its earliest days, the patent examiners in AU 1631 had di-
verse expertise not only in the biological sciences, but also in physics 
and electrical engineering and, most importantly, computer science.13 
The USPTO considered the software and data processing patent cases 
of the late 1990s14 directly relevant to patents on computing tools for 
analyzing biological systems, and accordingly advised bioinformatics 
inventors to draw lessons from the software invention guidelines in 
the Manual of Patent Examining Procedure (“MPEP”).15 Thus the 
rapid expansion of software patentability seen in that era directly af-
fected AU 1631. 
However, the art unit was also located in Technology Center 1600, 
which had just announced important, new, relatively strict examina-
tion guidelines on the so-called written description and utility re-
quirements.16 This latter group of guidelines presumably also had 
some impact on the behavior of examiners in AU 1631. 
This Article analyzes these dual influences in an early cohort of 
patent applications assigned to AU 1631. It first compares the charac-
teristics of these applications with a comparison group of applications 
from a related but more traditionally software-oriented data pro-
cessing art unit, AU 2123. Our analysis shows that on all conventional 
measures of technological importance, private value and quality, ap-
plications in AU 1631 were significantly different from and “better” 
than applications in AU 2123. To that extent, our results reinforce the 
empirical theme of considerable variation in the manner in which the 
system operates across technologies. 
The Article then compares the examination of applications from 
AU 1631 with a matched set of applications from AU 2123. On a 
sample of applications matched on various dimensions of private val-
                                                                                                                  
9. Id. 
10. See USPTO, PATENT TECHNOLOGY CENTERS MANAGEMENT, http://www.uspto.gov/ 
web/patents/contacts/tcmgrs.htm (last visited Dec. 17, 2015). 
11. Steinberg, supra note 7. 
12. Id. 
13. Id. 
14. See generally AT&T Corp. v. Excel Commc’ns Inc., 172 F.3d 1352 (Fed. Cir. 1999); 
State St. Bank & Tr. Co. v. Signature Fin. Grp. Inc., 149 F.3d 1368 (Fed. Cir. 1998). 
15. Steinberg, supra note 7. 
16. Revised Interim Guidelines for Examination of Patent Applications Under the 35 
U.S.C. § 112, ¶ 1 “Written Description” Requirement; Request for Comments, 64 Fed. Reg. 
71,427 (Dec. 21, 1999); Revised Utility Examination Guidelines; Request for Comments, 64 
Fed. Reg. 71,440 (Dec. 21, 1999). 
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ue and quality, patent prosecution in AU 1631, with its biology-
trained examiners, looked strikingly different from prosecution in AU 
2123. With the notable exception of nonobviousness rejections, appli-
cations in AU 1631 experienced more rejections, particularly notice-
related rejections, than a matched sample of applications in AU 2123.  
As we discuss, these differences in patent examination quality, 
particularly with respect to notice, appear to result from the biotech-
nology-specific examination guidelines that applied to examiners in 
AU 1631, as well as the higher educational attainment of these exam-
iners. Our results therefore have implications for improving patent 
examination quality. Specifically, our results suggest that the various 
pressures that operate against rigorous examination, including in the 
area of software, can be countered if properly trained examiners are 
given notice-enhancing tools that can be applied with relative ease, 
such as the written description and definiteness requirements. 
We conclude by linking our results to the literature discussing 
how the growing percentage of patent applications that rely on inter-
disciplinary and team-based science should be examined. 
Part II of the Article summarizes the robust debate surrounding 
patent quality and introduces the issue of measuring quality. Part III 
surveys the quality metrics that scholars and policymakers have em-
ployed in evaluating the USPTO’s performance as an ex ante guaran-
tor of patent quality. Part IV applies the quality metrics identified in 
Part III to more than five hundred patent applications from AU 1631 
and AU 2123 and discusses the significant differences identified be-
tween applications reviewed in these two art units. Part V elaborates 
on policy implications, both for patent quality and for how patent of-
fices should examine applications that increasingly rely on team-
based, interdisciplinary science. 
II. QUALITY IN THE PATENT OFFICE 
Much of the current dissatisfaction with the U.S. patent system 
stems from concerns about patent quality. Numerous commentators 
have put forward proposals for quality improvement.17 Some of the-
se — most notably, enhanced post-grant adjudications at the 
USPTO — were incorporated into the America Invents Act of 2011 
                                                                                                                  
17. See generally JAMES BESSEN & MICHAEL J. MEURER, PATENT FAILURE (2008); DAN 
L. BURK & MARK A. LEMLEY, THE PATENT CRISIS AND HOW THE COURTS CAN SOLVE IT 
(2009); ADAM B. JAFFE & JOSH LERNER, INNOVATION AND ITS DISCONTENTS (2004); Stuart 
Minor Benjamin & Arti K. Rai, Who’s Afraid of the APA? What the Patent System Can 
Learn from Administrative Law, 95 GEO. L.J. 269 (2007). 
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(“AIA”).18 The court system has acted on others.19 Even so, more re-
mains to be done. 
When critics bemoan poor quality, they are concerned about sev-
eral different issues.20 These include: failure to comply with the statu-
tory requirement that patents be granted only to inventions that would 
not be obvious to the ordinary scientist or technologist working in the 
area;21 failure to comply with the statutory requirement that the patent 
disclose how to make and use the full scope of the invention covered 
by the claims;22 and violation of the principle that the patent claims 
must give proper notice as to the boundary of the patent right.23 
Patent quality failures are perhaps most visible in litigation,24 due 
to patent litigation’s high costs,25 often unpredictable outcomes,26 and 
                                                                                                                  
18. Leahy-Smith America Invents Act, Pub. L. No. 112–29, 125 Stat. 284 (2011) (codi-
fied in scattered sections of 35 U.S.C.). 
19. For example, the Supreme Court in 2007 raised the nonobviousness standard for pa-
tentability by enabling patent examiners to combine prior art references and reject inven-
tions as obvious without strict application of the “teaching, suggestion, or motivation” test 
to make such combinations. See KSR Int’l. Co. v. Teleflex Inc., 550 U.S. 398, 419 (2007). 
20. For present purposes, we avoid the question of whether patents on certain types of in-
ventions are inherently “poor quality.” To be sure, the Supreme Court has clearly held that 
restrictions should be placed on patent-eligible subject matter. See, e.g., Alice Corp. Pty. Ltd. 
v. CLS Bank Int’l, 134 S. Ct. 2347, 2352 (2014); Ass’n for Molecular Pathology v. Myriad 
Genetics, Inc., 133 S. Ct. 2107, 2111 (2013); Mayo Collaborative Servs. v. Prometheus 
Labs., Inc., 132 S. Ct. 1289, 1294 (2012); Bilski v. Kappos, 561 U.S. 593, 611–12 (2010). 
21. See 35 U.S.C. § 103 (2012); KSR, 550 U.S. at 420 (2007) (finding that a patent on an 
adjustable automobile pedal assembly would, at the time of invention, have been obvious to 
one of ordinary skill in the field when considered in light of the available technology). 
22. See 35 U.S.C. § 112(a) (2012); Wyeth & Cordis Corp. v. Abbott Labs., 720 F.3d 
1380, 1382 (Fed. Cir. 2009) (affirming that a patent on a method for using immunosuppres-
sant rapamycin drugs to treat and prevent re-narrowing of arteries required excessive exper-
imentation and was therefore invalid under § 112(a) for nonenablement). 
23. See 35 U.S.C. §§ 112(b), (f) (2012); In re Packard, 751 F.3d 1307, 1309 (Fed. Cir. 
2014) (affirming the USPTO’s rejection of a patent application on a coin change holder 
under § 112(b) for indefiniteness); Power Integrations, Inc. v. Fairchild Semiconductor Int’l., 
Inc., 711 F.3d 1348, 1365 (Fed. Cir. 2013) (finding in pertinent part that patents on tech-
niques for mitigating electromagnetic interference and current flow problems recited suffi-
cient structure with respect to the term “soft start circuit” to satisfy the means-plus-function 
requirements of § 112(f)). The Federal Circuit has also adopted the view that the written 
description terminology of § 112(a) performs a notice function. Moreover, as discussed 
further below, although the court indicated in 2010 that written description applies to all 
technologies, during the time of this empirical study the requirement only appeared to apply 
to biotechnology and chemistry. See Ariad Pharm. et al. v. Eli Lilly & Co., 598 F.3d 1336, 
1349 (Fed. Cir. 2010) (en banc). 
24. See, e.g., Charles Duhigg & Steve Lohr, Fighters in a Patent War, N.Y. TIMES (Oct. 
7, 2012), http://www.nytimes.com/interactive/2012/10/08/business/Fighters-in-a-Patent-
War.html [http://perma.cc/23SS-ZV62] (summarizing a network of patent lawsuits among 
the top patent litigants in the smart phone industry since 2006). Controversial litigation 
arises not only in smartphones and software but also over genes. See, e.g., Brent Kendall, 
Myriad Genetics Presses Ahead After High Court Ruling on Patents, WALL ST. J.: L. BLOG 
(July 12, 2013), http://blogs.wsj.com/law/2013/07/12/myriad-genetics-presses-ahead-after-
high-court-ruling-on-patents/ [http://perma.cc/5YVK-B3VV]. 
25. Compare James Bessen & Michael J. Meurer, The Direct Costs from NPE Disputes, 
99 CORNELL L. REV. 387, 390 (2014) (estimating the direct costs to defendants from patent 
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potentially lasting dynamic losses to innovation.27 Yet because many 
of the more egregious harms from patent litigation are best understood 
as effects rather than causes of poor patent quality,28 one important 
locus of proposed reforms continues to be the USPTO infrastructure 
for initial patent examination.29 
Given the impossibility of systematically evaluating every patent 
that issues from the USPTO for compliance with novelty, nonobvi-
ousness, disclosure, and notice requirements, critics have pointed to 
various institutional features that would suggest poor quality. One set 
of institutional features prevents proper application of existing patent 
law standards. Another set may cause these standards to be too lax. 
Because both sets of institutional features provide the motivation for 
our empirical analysis of quality, we discuss them below. We then 
discuss how these institutional implications vary in technology-
specific ways. 
                                                                                                                  
assertions by non-practicing entities at about $29 billion in 2011), with David L. Schwartz 
& Jay P. Kesan, Analyzing the Role of Non-Practicing Entities in the Patent System, 99 
CORNELL L. REV. 425, 433 (2014) (critiquing the findings and methodology of Professors 
Bessen and Meurer as a likely upper bound and potentially biased upward). 
26. Both the literature and case law identify a variety of sources for unpredictability in 
patent litigation. See, e.g., J. Jonas Anderson & Peter S. Menell, Informal Deference: A 
Historical, Empirical, and Normative Analysis of Patent Claim Construction, 108 NW. U. L. 
REV. 1, 4–7 (2014) (discussing uncertainty in claim construction); Festo Corp. v. Shoketsu 
Kinzoku Kogyo Kabushiki Co., 535 U.S. 722, 723 (2002) (explaining that despite the uncer-
tainty that the doctrine of infringement by equivalents introduces into the patent system, the 
Court has repeatedly accepted such uncertainty “as the price of ensuring the appropriate 
incentives for innovation”); see also Alan C. Marco & Saurabh Vishnubhakat, Certain 
Patents, 16 YALE J.L. & TECH. 103, 132 (2013) (estimating the economic value of the cer-
tainty in patent rights that adjudicative resolution brings). 
27. The subject of dynamic and static impacts on innovation from patenting is both wide-
ly studied in its own right and widely applied to particular economic and legal situations. 
For a good overview, see generally Peter Lee, Toward a Distributive Commons in Patent 
Law, 2009 WIS. L. REV. 917 (2009); Mark A. Lemley, The Economics of Improvement in 
Intellectual Property Law, 75 TEX. L. REV. 989 (1997); Robert P. Merges & Richard R. 
Nelson, On the Complex Economics of Patent Scope, 90 COLUM. L. REV. 839 (1990); Su-
zanne Scotchmer, Standing on the Shoulders of Giants: Cumulative Research and the Patent 
Law, 5 J. ECON. PERSPS., Winter 1991, at 29. 
28. Cf. Mark A. Lemley & A. Douglas Melamed, Missing the Forest for the Trolls, 113 
COLUM. L. REV. 2117, 2120–21 (2013) (arguing that the effects of patent assertion by patent 
trolls, however defined, are a symptom of systemic flaws in the patent system). 
29. The situation post-grant appears to be quite different. Not only are the post-grant re-
view procedures set up by the AIA very heavily utilized, see AIA Trial Statistics, USPTO, 
http://www.uspto.gov/patents-application-process/appealing-patent-decisions/statistics/aia-
trial-statistics (last visited Dec. 17, 2015) (tabulating usage of the AIA patent validity chal-
lenge procedures from April through September 2015), but criticisms center around the idea 
that the procedures are too strict, not too lax. See, e.g., Ronald L. Grudziecki, Rapidly 
Changing Patent Law Landscape Requires Careful Attention from Attorneys, ASPATORE, 
May 2015 WL 3764843, at *3 (2015) (noting that the Patent Office “has received numerous 
complaints regarding amendment proceedings, because some patents probably could have 
been saved by further amendments, but the USPTO did not provide enough pages for 
amendment, and the requirements were overly strict”). 
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A. Improper Application of Patent Law Standards 
The USPTO operates under a number of institutional constraints 
that might cause application of existing patent law standards to be too 
lax. Perhaps most notably, examiners have a very limited amount of 
time to examine patents.30 Thus, fact-intensive patent law standards 
that involve significant work, such as thoroughly searching prior art to 
evaluate nonobviousness or thoroughly evaluating an application’s 
disclosure, may simply be too burdensome for examiners to imple-
ment successfully. Recent empirical work, discussed further in Part III, 
suggests that these time constraints become particularly restrictive as 
examiners advance in seniority.31 
Another reason for concern is the agency’s funding structure, 
which is not only entirely fee-based but also heavily based on fees 
paid only if a patent is granted.32 The USPTO currently charges $1600 
cumulatively for the filing, search, and examination of patent applica-
tions — even though the cost of doing this work is more than double 
that amount.33 More generally, in the period from 2001 to 2014, over 
half of the USPTO’s operating budget came from issuance fees that 
are paid only after an examiner deems a patent application allowable 
and from maintenance fees that are paid during the post-grant life of 
the patent; filing, search, and examination fees from new applications 
accounted for less than a third of the USPTO’s annual revenue.34 In 
fact, some empirical research suggests that categories of patents from 
which the USPTO is more likely to receive maintenance fees are also 
                                                                                                                  
30. See Michael D. Frakes & Melissa F. Wasserman, Is the Time Allocated to Review Pa-
tent Applications Inducing Examiners to Grant Invalid Patents?: Evidence from Micro-
Level Application Data 8–9 (Nat’l Bureau of Econ. Research Working Paper No. 20337, 
2014), http://www.nber.org/papers/w20337 [http://perma.cc/BVC6-FG3R]. 
31. See generally id. 
32. See, e.g., Arti K. Rai, Growing Pains in the Administrative State: The Patent Office’s 
Troubled Quest for Managerial Control, 157 U. PA. L. REV. 2051, 2062 (2009) (arguing 
that the USPTO’s fee structure “sets up an obvious financial incentive for the USPTO to 
grant patents”). 
33. The USPTO fee schedule for utility applications charges $280 for filing, $600 for 
search, and $720 for examination, totaling $1600. USPTO Fee Schedule, USPTO (Jan. 1, 
2014), http://www.uspto.gov/learning-and-resources/fees-and-payment/uspto-fee-schedule. 
What these activities cost the USPTO to perform, however, is considerably higher. These 
costs totaled $3569 in FY 2011, $3906 in FY 2010, and $3284 in FY 2009. USPTO, 
USPTO SECTION 10 FEE SETTING — ACTIVITY-BASED INFORMATION AND COSTING 
METHODOLOGY 18, http://www.uspto.gov/sites/default/files/aia_implementation/ 
aia_section_10_cost_supplement.pdf (last visited Dec. 17, 2015). 
34. From FY 2001 through FY 2014, annual revenues from maintenance and issue fees 
constituted 50% or more of total annual revenues, whereas annual revenues from filing, 
search, and examination fees constituted between 24% and 31%. See USPTO Annual Re-
ports, USPTO, http://www.uspto.gov/about-us/performance-and-planning/uspto-annual-
reports (last visited Dec. 17, 2015) (containing hyperlinks to Performance and Accountabil-
ity Reports from FY 2001–2014). 
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more likely to be granted.35 In the absence of a specifically-identified 
mechanism by which motivation for future economic gain might in-
fluence current USPTO behavior in particular patent areas, these find-
ings should be viewed cautiously. Nonetheless, given the USPTO’s 
fee structure, applying patentability criteria loosely would have a 
positive effect on USPTO funding. So would legal or policy decisions 
that affirmatively relaxed these criteria. In the next section, we exam-
ine other institutional pressures that might cause legal standards to be 
overly lax. 
B. Lax Patentability Standards 
Even absent substantive rulemaking authority, the USPTO has 
some ability to articulate the contours of patent law.36 Beyond merely 
exercising its discretion in the interstitial application of patent law to 
the facts of patent examination, the USPTO also frequently issues 
legal guidance documents to its examiners to interpret judicial deci-
sions and produces its own substantive precedents in the agency’s 
internal administrative appeals process.37 Though the Federal Circuit 
has, thus far, given no deference to these guidance documents or prec-
edents,38 the vanishingly small subset of USPTO actions that come 
before the Federal Circuit reflects further limitations on the court’s 
ability to actively manage the direction of substantive patent law.39 
Moreover, as noted above, the USPTO’s funding structure may give it 
an incentive to relax patentability standards. 
Another mechanism by which patentability standards may have 
become too lax involves the interaction between the USPTO and the 
Court of Appeals for the Federal Circuit prior to the passage of the 
America Invents Act of 2011. Prior to the AIA, the major route by 
which appeals from the USPTO came to the Federal Circuit was 
                                                                                                                  
35. Michael D. Frakes & Melissa F. Wasserman, Does Agency Funding Affect Deci-
sionmaking?: An Empirical Assessment of the PTO’s Granting Patterns, 66 VAND. L. REV. 
67, 69–71 (2013). 
36. Melissa F. Wasserman, The PTO’s Asymmetric Incentives: Pressure to Expand Sub-
stantive Patent Law, 72 OHIO ST. L.J. 379, 387–89 (2011). See also Arti K. Rai, Engaging 
Facts and Policy: A Multi-Institutional Approach to Patent System Reform, 103 COLUM. L. 
REV. 1035, 1131–33 (2003) (comparing the relative competencies of the Federal Circuit in 
judicial patent policymaking and the USPTO in administrative patent policymaking during 
the early 2000s). 
37. Wasserman, supra note 36, at 394–98. 
38. Id. at 383. But see Arti K. Rai, Improving (Software) Patent Quality Through the Ad-
ministrative Process, 51 HOUS. L. REV. 503, 540–43 (2013) (arguing that legal determina-
tions made in post-grant review proceedings set up by the AIA may merit Chevron 
deference). 
39. Wasserman, supra note 36, at 398–400. 
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through a decision by an applicant to appeal a rejection.40 Thus, the 
agency could be reversed only for improper rejections and not im-
proper grants. Under a model where the agency was motivated entire-
ly by the fear of Federal Circuit reversal, it would presumably reject 
only that small subset of applications that were seen as unpatentable 
even by the most “pro-patent” members of the Federal Circuit. The 
result would be a progressive lowering of patent standards. 
Although this model probably overstates the extent to which the 
USPTO is motivated by Federal Circuit reversal, and understates the 
extent to which it is influenced by the White House and by workload 
fears, the USPTO has, at times, certainly found itself beholden to 
Federal Circuit decisions that made it very difficult for the agency to 
deny patents.41 For example, during the time period covered by our 
study, the agency operated under a requirement that it show a written 
teaching, suggestion, or motivation (“TSM”) to combine prior art 
when making an obviousness rejection.42 As we discuss below, this 
TSM requirement may have had particular force for AU 1631, where 
prior art from the life sciences and software would presumably some-
times have to be combined to make an obviousness rejection. 
C. Quality and Technology-Specificity 
The debate over patent quality also has a technological dimension. 
This dimension is particularly relevant for purposes of our paper, as 
we explicitly address not simply a “recombinant” field but a field that 
combines two areas — biotechnology and software — historically 
considered quite different from a quality perspective. 
Although the United States has a unitary patent system with few 
formal exclusions or exceptions,43 the potentially wide-ranging differ-
ences among the economic and legal needs of various technology and 
industry sectors have made it necessary and appropriate for U.S. pa-
tent law to adopt doctrines that accommodate those differences.44 
Many substantive criteria for patentability operate by reference to 
a person having ordinary skill in the art (“PHOSITA”), analogous to 
                                                                                                                  
40. See Jonathan Masur, Patent Inflation, 121 YALE L.J. 470, 503 (2011); Wasserman, 
supra note 36, at 401–06. 
41. See generally Arti K. Rai, Who’s Afraid of the Federal Circuit?, 121 YALE L.J. 
ONLINE 335 (2011) (discussing the merits of Professor Masur’s inflationary model). 
42. See id.; see also DyStar Textilfarben GmbH & Co. v. C.H. Patrick Co., 464 F.3d 
1356 (Fed. Cir. 2006); In re Lee, 277 F.3d 1338 (Fed. Cir. 2002). 
43. COMM. ON INTELL. PROP., NAT’L RESEARCH COUNCIL, A PATENT SYSTEM FOR THE 
21ST CENTURY 45 (Stephen A. Merrill et al. eds., 2004). 
44. Id. 
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tort law’s reasonably prudent person,45 and so incorporate technology-
specific perspectives into nominally technology-agnostic standards.46 
The foundational role of the PHOSITA has, for example, resulted in a 
doctrine of “unpredictable arts” that tolerates in those arts a greater 
degree of experimentation for purposes of enablement47 and more 
readily accepts unlikely advances over the prior art for purposes of 
nonobviousness.48 Indeed, usage of the PHOSITA construct may itself 
be so fact-intensive as to produce doctrine that is overly technology-
specific,49 raising the normative question of how best to identify the 
PHOSITA.50 
Beyond the PHOSITA construct, the Federal Circuit’s historical 
tendency to apply the written description terminology of 35 U.S.C. 
§ 112(a) to biotechnology and chemistry, but not necessarily to other 
arts,51 had implications for both notice and scope. In the 1997 case of 
University of California v. Eli Lilly, the Federal Circuit held that, even 
for originally filed claims, written description was a requirement sepa-
                                                                                                                  
45. Panduit Corp. v. Dennison Mfg., 810 F.2d 1561, 1566 (Fed. Cir. 1987) (noting patent 
law’s reliance on “a ghost, i.e., ‘a person having ordinary skill in the art,’ not unlike the 
‘reasonable man’ and other ghosts in the law”). 
46. See 35 U.S.C. §§ 103, 112(a), 122(b)(2)(B)(v) (2012). See also Arti K. Rai, Building 
a Better Innovation System: Combining Facially Neutral Patent Standards with Therapeu-
tics Regulation, 45 HOUS. L. REV. 1037, 1045 (2008). 
47. See In re Wands, 858 F.2d 731, 736–37 (Fed. Cir. 1988). 
48. See Procter & Gamble v. Teva Pharm. USA, Inc., 566 F.3d 989, 996 (Fed. Cir. 2009). 
49. See generally Dan L. Burk & Mark A. Lemley, Is Patent Law Technology-Specific?, 
17 BERKELEY TECH. L.J. 1155 (2002). 
50. See, e.g., Jonathan J. Darrow, The Neglected Dimension of Patent Law’s PHOSITA 
Standard, 23 HARV. J.L. & TECH. 227, 240–45 (2009) (arguing that the PHOSITA standard 
has progressed from the tradesman “who practiced his art with ordinary skill but was not an 
inventor” to the designer “whose work required a significant effort of the brain” to an inapt 
researcher model that under-rewards innovation in the useful arts by defining the relevant 
art itself in terms of innovative activity). 
51. See, e.g., Moba v. Diamond Automation, Inc., 325 F.3d 1306 (Fed. Cir. 2003) (per 
curiam), cert. denied, 540 U.S. 982 (2003). In Moba, Judge Rader wrote separately to note, 
inter alia, that the written description requirement as interpreted in the Federal Circuit’s 
jurisprudence had “create[d] a technology-specific rule in a technology-neutral statute.” Id. 
at 1327 (Rader, J., concurring). Commentators have agreed with this assessment as well. See, 
e.g., Burk & Lemley, supra note 49; Ajeet P. Pai, The Low Written Description Bar for 
Software Inventions, 94 VA. L. REV. 457 (2008). In contrast, a 2007 paper by Chris Holman 
uses data from appeals of patent rejections to the internal USPTO appeals board (then called 
the Board of Patent Appeals and Interferences, or BPAI) to argue that written description 
has not necessarily played an important role. Christopher M. Holman, Is Lilly Written De-
scription a Paper Tiger: A Comprehensive Assessment of the Impact of Eli Lilly and Its 
Progeny in the Courts and PTO, 17 ALB. L.J. SCI. & TECH. 1 (2007). Holman emphasizes 
the small number of BPAI decisions that address written description. However, to the extent 
that written description is a relatively bright-line rule, a rejection that appears correct under 
the application of that rule may not be appealed at all. E.g., Kate S. Gaudry & Joseph J. 
Mallon, Appeals and RCEs — The Frequency and Success of Challenges to Specific Rejec-
tion Types, INTELL. PROP. TODAY, Nov. 2011, at 28 (finding that after a final rejection by 
the examiner, applicant appeals to the BPAI as well as applicant requests for continued 
examination relied quite infrequently on § 112 grounds such as written description or ena-
blement). 
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rate from enablement.52 The Federal Circuit also held that a genus 
claim (in that case a functional genus claim to cDNA that coded for 
insulin) satisfied written description only to the extent that it included 
the structure of a subset of species representative of the genus.53 The 
USPTO’s Written Description Guidelines, issued in draft form in 
1999 and finalized in 2001,54 relied heavily on this precedent, stress-
ing that the structure of a “representative number of species” was nec-
essary to claim the genus.55 
To the extent that the written description requirement has been 
applied more to biotechnology and chemistry than to other arts,56 it 
has arguably generated better boundary notice and more appropriately 
tailored scope in biotechnology and chemistry. Boundary notice in 
chemistry — though not necessarily in biotechnology — may also 
reflect the discipline’s well-standardized conventions of nomencla-
ture.57 In contrast, the relatively imprecise vocabulary of software-
related inventions requires greater standardization through bodies, 
such as the Institute of Electrical and Electronics Engineers 
(“IEEE”).58 
Additionally, because technology is itself malleable in definition, 
imposing a priori classifications may compound the already difficult 
task of comparing patent quality across different arts.59 One aspect of 
this problem is that inventions that are truly seminal in a new field 
                                                                                                                  
52. 119 F.3d 1559, 1566 (Fed. Cir. 1997). 
53. Id. at 1566–69 (invalidating functional genus claim to insulin cDNAs because the 
written description failed to recite enough species to constitute a “substantial portion of the 
genus”). 
54. Guidelines for Examination of Patent Applications Under the 35 U.S.C. § 112, ¶ 1, 
“Written Description” Requirement, 66 Fed. Reg. 1099, 1106 (Jan. 5, 2001).  
55. Id. 
56. See Margaret Sampson, The Evolution of the Enablement and Written Description 
Requirements under 35 U.S.C. 112 in the Area of Biotechnology, 15 BERKELEY TECH. L.J. 
1233, 1234–36 (2000). However, the Federal Circuit’s en banc decision in Ariad Pharm. v. 
Eli Lilly & Co., handed down in 2010, does purport to make written description a require-
ment that applies equally to all technology. 598 F.3d 1336 (Fed. Cir. 2010) (en banc). 
57. BESSEN & MEURER, PATENT FAILURE, supra note 17, at 152–53. But see generally 
William D. Marsillo, How Chemical Nomenclature Confused the Courts, 6 U. BALT. INTELL. 
PROP. L.J. 29 (1997) (arguing that where a genus of chemical compounds is to be claimed 
by reference to a few representative species, the rules of chemical nomenclature have creat-
ed judicial confusion about theoretical permutations of chemical structure and the practical 
import of actual chemical and physical properties). 
58. See Peter S. Menell & Michael J. Meurer, Notice Failure and Notice Externalities, 5 J. 
LEGAL ANALYSIS 1, 36 (2013) (comparing IEEE’s efforts in this regard to similar scientific 
governance provided by the International Union of Pure and Applied Chemistry). 
59. For example, what medical researchers may reliably have denoted “oncology” a cen-
tury ago is now an immensely broad collection of well-developed disciplines defined by 
affected populations (e.g., pediatric oncology addressing cancer in children and geriatric 
oncology addressing cancer in the elderly), affected biological systems (e.g., hematology-
oncology addressing blood-related cancers), and, in the case of personalized medicine, even 
individual genomes. Modern science can no longer discuss inventions in the field of oncol-
ogy.  
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pose a challenge for measuring quality because, by their very nature, 
they are quite broad in scope.60 Distinguishing broad patents from 
overbroad patents is difficult.61 Evaluating the quality of such patents 
is similarly difficult. Another aspect of the problem is that general-
purpose technologies, such as software, serve as platforms for, or in-
puts into, a wide variety of other fields,62 and inventions in these 
widely adopted arts are not easily identified in objective and replica-
ble ways.63 
This general debate over the importance of technology in patent 
law informs a variety of specific patent quality discussions including 
proposals for technology-agnostic64 and explicitly category-based65 
reforms alike. Prominent among these proposals is the desire particu-
larly to assess the quality of software-related patents66 and to improve 
it.67 These discussions raise a threshold boundary definition prob-
                                                                                                                  
60. See Matthew J. Conigliaro, Andrew C. Greenberg & Mark A. Lemley, Foreseeability 
in Patent Law, 16 BERKELEY TECH. L.J. 1045, 1049–53 (2001) (describing pioneer inven-
tions as distinct from more incremental technological improvements and proposing a heuris-
tic for according due scope and protection to patents on pioneer inventions). But see 
generally Brian J. Love, Interring the Pioneer Invention Doctrine, 90 N.C. L. REV. 379 
(2012) (arguing from historical discussion that truly pioneering inventions do not exist and 
that patent law should formally abrogate the doctrine of giving broad protection to pioneer 
inventions). 
61. See Apple Inc. v. Motorola, Inc., 757 F.3d 1286, 1334–38 (Fed. Cir. 2014) (Prost, J., 
concurring in part, dissenting in part) (discussing the need either to require adequate struc-
tural information in the patent or to apply means-plus-function treatment under 35 U.S.C. 
§ 112(f), or else invite problems of overbroad patenting). 
62. Stuart J.H. Graham & Maurizio Iacopetta, Nanotechnology and the Emergence of a 
General Purpose Technology, 115/116 ANNALS OF ECONS. & STATS. 5, 8 (2014), 
http://www.ssrn.com/abstract=1334376 [http://perma.cc/6S3N-AZU9]; Stuart J.H. Graham 
& Saurabh Vishnubhakat, Of Smart Phone Wars and Software Patents, 27 J. ECON. PERSPS. 
67, 74–75 (2013). See generally Timothy F. Bresnahan & Manuel Trajtenberg, General 
Purpose Technologies: “Engines of Growth?” 65 J. ECONOMETRICS 83, 83–85 (1995) 
(articulating the characteristics of general purpose technologies). 
63. For a discussion of the methodological tradeoffs between reaching an accurate defini-
tion of software patents that minimizes Type I and Type II errors and reaching a precise 
definition that is reproducible despite potential errors, see Bronwyn H. Hall & Megan Mac-
Garvie, The Private Value of Software Patents 13–17 (NBER Working Paper No. 12195, 
May 2006), http://www.nber.org/papers/w12195 [http://perma.cc/5H8D-NBR8]. See also 
Arti K. Rai, John R. Allison & Bhaven N. Sampat, University Software Ownership and 
Litigation: A First Examination, 87 N.C. L. REV. 1519, 1526–33 (discussing Type I and 
Type II errors in various definitions). 
64. E.g., Jaffe & Lerner, supra note 17. 
65. E.g., Peter S. Menell, A Method for Reforming the Patent System, 13 MICH. 
TELECOMM. & TECH. L. REV. 487 (2007). 
66. See John R. Allison, Abe Dunn & Ronald J. Mann, Software Patents, Incumbents, 
and Entry, 85 TEX. L. REV. 1579, 1581 (2007) (framing proposed reforms for patents on 
software-related inventions in terms of the “varying uses to which software firms put patents 
in their businesses”); see also John R. Allison & Ronald J. Mann, The Disputed Quality of 
Software Patents, 85 WASH. U. L. REV. 297 (2007). 
67. Julie E. Cohen & Mark A. Lemley, Patent Scope and Innovation in the Software In-
dustry, 89 CAL. L. REV. 1, 3–4 (2001) (arguing for ex post tailoring of scope in software-
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lem,68 which invites general reforms of patent quality that would dis-
proportionately affect patents on software-related inventions in a posi-
tive way,69 as well as software-specific reforms.70 
More generally, quality concerns have spawned numerous pro-
posals for reform. Some of these proposals, such as significantly en-
hanced post-grant review of issued patents, have already been 
implemented in the AIA. Others, particularly with respect to notice, 
have yet to be attempted or have been implemented only in pilot form. 
We defer discussion of future potential reforms to Part V, when we 
turn to policy implications of our empirical findings.  
In the next Part, we review efforts to measure patent quality quan-
titatively. Although these empirical studies do not necessarily lead 
directly to specific normative conclusions, they provide important 
background for our own empirical work. 
III. MEASURING PATENT QUALITY 
The challenge of describing patent quality in qualitative terms is 
matched by the challenge of describing and estimating patent quality 
through quantitative measures. Some of the difficulty arises because 
the empirical literature has not always distinguished carefully between 
at least three distinct visions of quality: (1) a patent document that is 
“important” and facilitates diffusion of knowledge; (2) the private 
value of a patent to the patent owner; and (3) a patent’s conformance 
with existing legal criteria for patentability. 71  Additionally, an 
emerging empirical literature views quality through the lens of exam-
iner characteristics and incentives that affect the rigor of examina-
tion.72 
Below we review the quantitative measures in the existing litera-
ture, with a focus on those measures that will help us evaluate both 
incoming patent applications to AU 1631 and AU 2123, and the ef-
                                                                                                                  
related patents through a limited right to reverse-engineer as well as a narrow application of 
the doctrine of equivalents). 
68. Colleen V. Chien, Reforming Software Patents, 50 HOUS. L. REV. 325, 354–55 (2012) 
(discussing the problem of defining software patents and noting some of the foundational 
legal literature on proposed definitions). 
69. See generally Rai, supra note 38, at 5–8. 
70. Kevin Emerson Collins, Patent Law’s Functionality Malfunction and the Problem of 
Overbroad, Functional Software Patents, 90 WASH. U. L. REV. 1399, 1400–02 (2013); 
Mark A. Lemley, Software Patents and the Return of Functional Claiming, 2013 WISC. L. 
REV. 905, 907–08 (2013). 
71. See Ronald J. Mann & Marian Underweiser, A New Look at Patent Quality: Relating 
Patent Prosecution to Validity, 9 J. EMPIRICAL L. STUD. 1, 2–4 (2012) (discussing literature 
on knowledge diffusion and private value but focusing on legal validity); see also R. Polk 
Wagner, Understanding Patent-Quality Mechanisms, 157 U. PA. L. REV. 2135, 2138–39 
(2009) (distinguishing between patent quality and private patent value). 
72. See infra Section III.D. 
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fects of examination. As we discuss in Part IV, we have data on the 
characteristics of incoming applications and on how those applica-
tions were examined. At the art unit level, we also have data on a va-
riety of examiner characteristics. 
A. Citations and Knowledge Transfer 
The literature tabulating forward citations of patents73 stresses the 
patent’s role in diffusing scientific or technical knowledge in a given 
community. On this view, patents that are highly cited by other pa-
tents are likely to be important.74 One factor that is positively corre-
lated with forward citation rates, and with technological importance 
more generally, is the number of co-inventors.75 For this reason, in 
Part IV we use numbers of inventors as one metric for evaluating in-
coming patent applications. 
                                                                                                                  
73. See, e.g., Bronwyn H. Hall, Adam B. Jaffe & Manuel Trajtenberg, The NBER Patent 
Citations Data File: Lessons, Insights and Methodological Tools (NBER Working Paper No. 
8498, Oct. 2001), http://www.nber.org/papers/w8498.pdf [http://perma.cc/P4J7-9FDN]; 
Adam B. Jaffe, Manuel Trajtenberg & Rebecca Henderson, Geographic Localization of 
Knowledge Spillovers as Evidenced by Patent Citations, 108 Q.J. ECON. 577, 577 (1993). 
Numerous legal scholars have invoked this work in their own utilization of citation metrics. 
See, e.g., James Malackowski & Jonathan A. Barney, What Is Patent Quality? A Merchant 
Banc’s Perspective, 43 LES NOUVELLES 123, 130–31 (2008); Yasin Ozcan & Shane Green-
stein, Composition of Innovative Activity in ICT Equipment R&D, 45 LOY. U. CHI. L.J. 479, 
493 (2013); Michael Risch, Patent Troll Myths, 42 SETON HALL L. REV. 457, 477–80 
(2012). 
74. See Malackowski & Barney, supra note 73, at 131–30. More formally, a higher de-
gree of citation (adjusted for time lag) should correspond with greater private value in the 
patent for its owner. We note a recent empirical study that challenges this empirical assump-
tion. See David S. Abrams, Ufuk Akcigit & Jillian Popadak, Patent Value and Citations: 
Creative Destruction or Strategic Disruption? (Penn Inst. Econ. Res., Working Paper No. 
13-065, Nov. 2013), http://economics.sas.upenn.edu/system/files/13-065.pdf 
[http://perma.cc/D5EH-MZB3] (finding that forward citation rates reflect growing private 
value only initially, but later correspond to strategic behavior aimed at preserving the re-
turns from past patenting and to an overall decline in value). Though this study presents a 
compelling early criticism of the citation-value literature, its applicability is limited in im-
portant respects. The underlying data is based on the patent portfolios of non-practicing 
entities, whose reliance on licensing is a structurally different use of patent rights than by 
practicing entities such as manufacturers, who gain more from actually excluding competi-
tors from the market than from merely threatening to exclude as leverage in a licensing 
negotiation. The underlying data is also proprietary, making it difficult to reproduce or even 
operationalize the findings into a more complete empirical model. This is not to suggest that 
the findings themselves are incorrect, but that further, replicable research is needed before 
the prevailing understanding of citations and value is properly discarded. 
75. See Lee Fleming & Jasjit Singh, Lone Inventors as Sources of Breakthroughs: Myth 
or Reality?, 56 MGMT. SCI. 41, 54 (2010) (arguing that a larger team increases the likeli-
hood of a breakthrough and decreases the likelihood of a relatively useless invention); Stef-
an Wuchty, Benjamin F. Jones & Brian Uzzi, The Increasing Dominance of Teams in 
Production of Knowledge, 316 SCIENCE 1036, 1036–37 (2007). 
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The citation literature has also generated quality proxies, such as 
technological originality and generality of the invention.76 Despite the 
difficulty of separating out such general-purpose technology patents 
for analysis,77 their presence in the background of so many different 
technologies makes them measurable in their influence and impact. 
Based on these insights, originality and generality have been dis-
cussed as correlate measures of patent quality.78 
Recent empirical analysis has shown, however, that examiners 
have a very significant influence on citations, and this influence is not 
randomly distributed.79 Thus, it is unclear how citation data that pools 
applicant and examiner citations should be interpreted. Indeed, one 
study focused on variation among examiners found that examiners 
whose patents were subsequently invalidated by the Federal Circuit 
on average issued patents that were more frequently cited.80 
For our purposes, because we focus on the quality of incoming 
patent applications and of examination, the forward citation metric is 
not relevant. On the other hand, as further discussed below, numbers 
of backward citations to prior art perhaps intuitively address a basic 
sense of quality.81 Particularly relevant for our purposes, applicant-
provided backward citations may be a proxy for the care with which 
the applicant drafted the application. In Part IV, we use applicant cita-
tions to prior art (both patents and non-patent literature) to evaluate 
incoming applications. 
B. Private Value 
The literature has often proxied for private value by looking at the 
characteristics of patents that are litigated or for which renewal fees 
are paid.82 In both cases, the assumption has been that rational parties 
would not incur associated expenditures without some expectation of 
                                                                                                                  
76. See generally Hall et al., supra note 73 (deriving these measures from analysis of 
time-adjusted citations). 
77. In the context of software, the definition in most recent growing use relies on a de-
tailed sorting at the level of U.S. patent class and subclass to mitigate over- and under-
counting. See Graham & Vishnubhakat, supra note 62, at 75 n.7. 
78. E.g., Josh Lerner, The Litigation of Financial Innovations, 53 J.L. & ECON. 807, 825 
(2010). 
79. Juan Alcácer, Michelle Gittelman & Bhaven Sampat, Applicant and Examiner Cita-
tions in U.S. Patents: An Overview and Analysis, 38 RES. POL’Y 415 (2009). 
80. See Iain M. Cockburn, Samuel Kortum & Scott Stern, Are All Patent Examiners 
Equal? The Impact of Characteristics on Patent Statistics and Litigation Outcomes, in 
PATENTS IN THE KNOWLEDGE-BASED ECONOMY 19, 22 (Wesley M. Cohen & Stephen A. 
Merrill eds., 2003). 
81. Mann & Underweiser, supra note 71. 
82. E.g., John R. Allison, Mark A. Lemley, Kimberly A. Moore & R. Derek Trunkey, 
Valuable Patents, 92 GEO. L.J. 435, 437–38 (2004); Kimberly A. Moore, Worthless Patents, 
20 BERKELEY TECH. L.J. 1521 (2005). 
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a return on investment. This literature has determined that litigated 
and renewed patents generally have higher numbers of claims as well 
as higher rates of forward and backward citation.83 Some commenta-
tors have therefore used number and complexity of claims not simply 
as a reflection of private value but also as a proxy for effort expended 
in obtaining the patent.84 Similarly, in Part IV, we use number of 
claims at filing as a proxy for effort initially expended by the appli-
cant.85 
Another important variable clearly correlated with private patent 
value is the size of the patent family — that is, the number of foreign 
jurisdictions in which the applicant has concurrently sought patent 
protection for the same invention.86 We also rely on this variable in 
Part IV. 
C. Legal Validity 
A third body of work examines the extent to which a particular 
patent, examiner, or set of examination characteristics correlate with a 
subsequent finding of legal validity. For purposes of what the USPTO 
aims to do, the legal validity question is the most important. The va-
lidity metric is limited, however, by the very significant selection bias 
involved in cases that are litigated to a final validity determination by 
the Federal Circuit. 87  The patent-level characteristics that predict 
whether the small subset of patents litigated all the way to the Federal 
Circuit will be found valid or invalid may not necessarily predict out-
comes with respect to the much larger pool of issued patents.88 
                                                                                                                  
83. Allison et al., supra note 82, at 438; Moore, supra note 82, at 1530. 
84. E.g., David S. Abrams & R. Polk Wagner, Poisoning the Next Apple? The America 
Invents Act and Individual Inventors, 65 STAN. L. REV. 517, 551 (2013). 
85. Importantly, our use of the number of claims at filing is not a proxy for private value 
per se. The private value literature considers the number of claims at issuance, and re-
striction requirements by examiners to divide an application’s claims into separate applica-
tions are particularly common in the fields of biotechnology and pharmaceuticals. As a 
result, the number of claims at filing may not reflect private value because such a number 
may differ from the number of claims at issuance. Yet the number of claims at filing does 
reflect an applicant’s expectation, at the time of filing, of future private value in the pa-
tent — and so it is a reasonable proxy for applicant effort expended in producing a more 
detailed, higher-quality application. See Abrams & Wagner, supra note 84, at 551 (includ-
ing the total number of claims in the empirical analysis, expecting “a higher-quality patent 
to be more detailed, and thus have more claims”). 
86. See, e.g., Dietmar Harhoff, Frederic M. Scherer & Katrin Vopel, Citations, Family 
Size, Opposition and the Value of Patent Rights, 32 RES. POL’Y 1343 (2003). 
87. See James Bessen & Michael J. Meurer, Lessons for Patent Policy from Empirical 
Research on Patent Litigation, 9 LEWIS & CLARK L. REV. 1, 4 (2005). 
88. That said, there is no reason to believe that the factors that predict validity or invalid-
ity in the subset of patents that reaches the Federal Circuit are strongly correlated with the 
factors that determine review by the Federal Circuit in the first instance. Mann & Under-
weiser, supra note 71, at 22–23. 
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Bearing this caveat in mind, it is nonetheless worth noting that 
one variable that is positively correlated with a finding of validity is 
applicant-submitted prior art references.89 Indeed, the presence of ap-
plicant-submitted prior art references is a sufficiently prominent met-
ric that some scholars have thoroughly analyzed applicant behavior 
across different technologies.90 The evidence indicates that applica-
tions in certain technology areas benefit from much more applicant-
supplied prior art than applications in other areas. For example, in a 
sample of patents issued between January 1, 2001 and December 31, 
2003, 45% of patents in the computers/communications and electri-
cal/electronic fields contained examiner-only citations compared to 
only 25% of drug and medical patents and 30% of chemical patents.91 
D. Examiner Characteristics 
An emerging body of literature examines the interaction between 
examiner characteristics and patent quality. Like the role of technolo-
gy, the role of examiners in patent quality is complex. Because many 
aspects of an examiner’s work are technology-specific, the examiner 
must at least be trained in a relevant science or engineering-related 
discipline.92 As a consequence, we would expect to see at least some 
variation in examiner characteristics. Indeed, as we discuss further in 
Part IV, such variation appears to be a key factor in our results.  
Beyond subject matter, however, institutional incentives also re-
sult in considerable variation in examiner behavior — variation that 
has important implications for patent quality.93 For example, experi-
ence level could affect quality, and the correlation might be either 
positive, because veteran examiners deliver more well-informed re-
views, or negative, because beginning examiners pay greater attention 
to details than veterans. Experience also affects time allocated to ex-
aminers. Under a time allocation grid that has not been significantly 
                                                                                                                  
89. Mann & Underweiser, supra note 71, at 18. 
90. Alcácer et al., supra note 79, at 419–20. 
91. Id. The technological field effects were robust to nationality, assignee size, and other 
factors. Id. For further detailed analysis of prior art supplied by applicants at the time of 
filing, see generally Bhaven N. Sampat, When Do Applicants Search for Prior Art?, 53 J.L. 
& ECON. 399 (2010). 
92. Examiners in the mechanical engineering field, for example, must be proficient in 
core subjects including differential and integral calculus, statics and dynamics, fluid me-
chanics and hydraulics, thermodynamics, electrical fields and circuits, properties and 
strengths of materials, and optics. See Job Announcement No. CP-2014-0034, USAJOBS 
(Mar. 21, 2014), http://www.usajobs.gov/GetJob/ViewDetails/365088500 
[http://perma.cc/ZM6Z-HHE7]. 
93. See Cockburn et al., supra note 80. 
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revised since 1976,94 examiners at higher GS-levels within a given art 
unit are allocated substantially less time to review applications than 
examiners at lower GS-levels.95 Time pressure could exacerbate any 
potential “burn out” felt by veterans. 
Analysis at the individual examiner level is possible because, 
within an art unit, applications appear to be randomly assigned.96 One 
complication, however, is the reality that multiple examiners within 
an art unit typically work on a single application. Primary examiners 
who have authority to issue actions in their own name supervise and 
sign off on the work of assistant examiners.97 Supervisory patent ex-
aminers oversee the work of entire art units98 in order to create more 
uniformity in examiner performance.99 
Despite this complication, some scholars have looked at individu-
al examiner characteristics. In one study that attributed patent exami-
nation to the assistant examiner when there was one, and to the prima-
primary examiner if there was no assistant examiner, Professors Mark 
Lemley and Bhaven Sampat found that years of examiner experience 
at the USPTO at the time of patent examination correlated inversely 
with number of prior art references added and positively with grant 
rate.100 More recently, Professors Michael Frakes and Melissa Was-
serman, studying individual examiners as they moved up the GS-level 
ranks, found a similar trend in decreased examiner effort, and argued 
that it emerges from unduly stringent time constraints placed by the 
USPTO’s production quota system on higher-level examiners.101 
                                                                                                                  
94. Patent Examiner Count System, USPTO, http://www.uspto.gov/patent/ 
initiatives/patent-examiner-count-system (last visited Dec. 17, 2015) (noting that “the last 
substantive change to the examiner goals was made over 30 years ago in 1976”). 
95. Frakes & Wasserman, supra note 30. GS-level indicates General Schedule Pay Scale 
for various government employees. 
96. See Mark A. Lemley & Bhaven Sampat, Examiner Characteristics and Patent Office 
Outcomes, 94 REV. ECON. & STAT. 817, 822 (2012). 
97. U.S. Patent & Trademark Office, Manual of Patent Examining Procedure § 707.01 
(9th ed. Rev. 7, Mar. 2014) [hereinafter MPEP]. 
98. See Patent Technology Centers Management, USPTO, http://www.uspto.gov/ 
patent/contact-patents/patent-technology-centers-management (last visited Dec. 17, 2015) 
(listing supervisory patent examiners by art unit). 
99. The effectiveness of these and related efforts at uniformity is the subject of ongoing 
discussion and improvement. See, e.g., Todd J. Zinser, Memorandum for Director David J. 
Kappos on the USPTO Patent Quality Assurance Process (Final Report No. OIG-11-006-I), 
U.S. DEP’T OF COMMERCE OFFICE OF THE INSPECTOR GEN. (Nov. 5, 2010), 
http://www.oig.doc.gov/OIGPublications/OIG-11-006-I.pdf [http://perma.cc/T9XY-WZ78] 
(summarizing recommendations for improving the agency’s examination quality assurance 
standards). Notably, although the input of several different examiners into patent examina-
tion is a challenge for studies that rely on the individual examiner as the unit of analysis, it 
poses less of a challenge for our study, which takes the art unit as the unit of analysis. 
100. Lemley & Sampat, supra note 96. 
101. Frakes & Wasserman, supra note 30, at 3–5. 
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IV. BIOINFORMATICS AT THE USPTO: AN EMPIRICAL VIEW 
This Part applies the quantitative patent quality literature dis-
cussed in Part III to an early cohort of patent applications from AU 
1631 and a comparison group, AU 2123. We use the patent quality 
measures identified above both to evaluate applications coming into 
AU 1631 and AU 2123 and to isolate the effects of the examination 
process on these applications. 
A. Technology and Comparison Group 
In general, AU 1631 broadly covers inventions combining biolo-
gy with computer implementation. The unit encompasses algorithms 
that predict gene function and protein folding and the application of in 
silico screening assays for identifying drug candidates.102  
To understand more precisely what the USPTO does and does not 
regard as bioinformatics technology, and why AU 2123 is a reasona-
ble comparison group, it is helpful to compare two classification sys-
tems that the USPTO employs. One is the United States Patent 
Classification (“USPC”) system describing the technological fields to 
which inventions pertain.103 The other is the USPTO Technology 
Center system, which describes the organizational division of art units 
that are responsible for patent examination.104 When the USPTO re-
ceives a patent application, the Office of Patent Classification both 
categorizes it as to the technology class or classes that the claimed 
invention best represents and assigns it to the art unit best suited to 
examine it.105 Not surprisingly, there is a close concordance between 
the USPC and the USPTO art unit hierarchy.106 According to this 
                                                                                                                  
102. The unit excludes biomedical imaging and simulation of organ functioning. 
103. The USPC is not the only technology classification system maintained by the 
USPTO — the International Patent Classification (“IPC”) system has long been in use as 
well, and the Cooperative Patent Classification (“CPC”) system is the most recent initiative 
for a harmonized taxonomy among the major patent systems. Classification Standards and 
Development, USPTO, http://www.uspto.gov/patents/resources/classification (last visited 
Dec. 17, 2015).  
104. See generally Patent Technology Centers, USPTO, http://www.uspto.gov/ 
about/contacts/phone_directory/pat_tech (last visited Dec. 17, 2015). They are also referred 
to as Patent Examiner Group Centers. See Office of the Deputy Commissioner for Patent 
Operations, USPTO, http://www.uspto.gov/about-us/organizational-offices/office- 
commissioner-patents/office-deputy-commissioner-patent (last visited Dec. 17, 2015). 
105. See U.K. INTELL. PROP. OFFICE & U.S. PATENT & TRADEMARK OFFICE, PATENT 
BACKLOGS, INVENTORIES AND PENDENCY: AN INTERNATIONAL FRAMEWORK 18 (2013), 
http://www.ipo.gov.uk/ipresearch-uspatlog-201306.pdf [http://perma.cc/JUM7-XB2G] 
(noting that applications received by the patent office first undergo pre-examination formali-
ties such as docketing and allocation according to relevant technology classification sys-
tems).  
106. See Patent Classification: Classes Arranged by Art Unit, USPTO (Aug. 2015), 
http://www.uspto.gov/patents-application-process/patent-search/understanding-patent- 
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concordance, bioinformatics inventions examined in AU 1631 are 
classified into subsets of U.S. patent class 703 pertaining to data pro-
cessing.107 Traditional software informatics inventions examined in 
AU 2123 are classified similarly.108 The two art units do not overlap 
in the subclasses they cover. Between them, the art units cover class 
703, as Table 1 summarizes. 
Discussions with USPTO staff familiar with bioinformatics exam-
ination confirmed that AU 2123 is a closely complementary art unit to 
AU 1631. USPTO staff noted, for example, that examiners in the two 
art units sometimes share cases.109 In addition, because the technology 
in each of the art units has been assigned the same class by the 
USPTO, an examiner at a given GS-level in AU 1631 is given the 
same amount of time to review an application as an examiner at the 
same GS-level in AU 2123.110 
Table 1: U.S. Patent Classes and Subclasses Mapped to  
AUs 1631 and 2123 
Class 703 (Data Processing: Structural Design, Modeling,  
Simulation, and Emulation) 
Subclass Title AU 1631 AU 2123 
1 Structural Design  × 
2 Modeling by Mathematical Expression  × 
3 Electrical Analog Simulator  × 
4 Of Electrical Device or System  × 
5 Of Physical Phenomenon (e.g., Heat, Wave, Geophysics)  × 
6 Simulating Nonelectrical Device or System  × 
7 Mechanical  × 
8 Vehicle  × 
                                                                                                                  
classifications/patent-classification.html (providing a crosswalk between the two taxono-
mies). 
107. Classes Arranged by Art Unit: Art Units 1611–1763, USPTO, 
http://www.uspto.gov/patents-application-process/classes-arranged-art-unit-art-units-1611- 
1763.html (last visited Dec. 17, 2015). 
108. Classes Arranged by Art Unit: Art Units 1764–2691, USPTO, 
http://www.uspto.gov/patents-application-process/classes-arranged-art-unit-art-units-1764- 
2691.html (last visited Dec. 17, 2015). 
109. Interview with Marjorie Moran, AU 1631 Supervisory Patent Examiner, and George 
Elliott, former Technology Center 1600 Director (Oct. 19, 2013) (notes on file with author 
Arti K. Rai) [hereinafter Interview with Moran and Elliot]. 
110. See Rai, supra note 32, at 2062–63 (discussing allotment of time by GS-level and 
technology class). 
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9 Fluid  × 
10 Well or Reservoir  × 
11 Biological or Biochemical ×  
12 Chemical ×  
13 Simulating Electronic Device or Electrical System  × 
14 Circuit Simulation  × 
15 Including Logic  × 
16 Event-Driven  × 
17 Event-Driven  × 
18 Power System  × 
19 Timing  × 
20 Target Device  × 
21 Computer or Peripheral Device  × 
22 Software Program (i.e., Performance Prediction)  × 
23 Emulation  × 
24 Of Peripheral Device  × 
25 I/O Adapter (e.g., Port, Controller)  × 
26 Of Instruction  × 
27 Compatibility Emulation  × 
28 In-Circuit Emulator (I.E., ICE)  × 
 
However, though the technology in the applications allocated to 
the two art units is comparable, applications received in the two art 
units may not necessarily be comparable. As noted previously, drugs, 
medicine, and chemistry all represent areas where applicants have 
historically supplied significantly more prior art than in electronics 
and communications.111 Whether or not bioinformatics applications 
resembled drugs, medicine, and chemistry in this respect was a propo-
sition we tested. 
In addition, we tested for differences in patent examination based 
on examiner characteristics at the level of the art unit. On average, 
patent examiners in the two art units differ in several ways that may 
be meaningful. Given AU 1631’s biological sub-focus within infor-
matics, examiners in that art unit are primarily trained in a biological 
science with additional relevant expertise in computer science, rather 
than primarily trained in computer science as AU 2123 examiners 
are.112 USPTO staff also indicated that AU 1631 has more examiners 
                                                                                                                  
111. See supra Part III.C. 
112. Interview with Moran and Elliot, supra note 109. 
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who hold advanced degrees than AU 2123: approximately 55% to 
60% of AU 1631 examiners have Ph.D. degrees and up to 90% have 
master’s degrees.113 
In this regard, personnel data obtained through Freedom of In-
formation Act (“FOIA”) requests, and generously provided to us by 
Professor Ronald Mann, showed differences in the personnel in the 
respective art units. Specifically, the thirteen examiners in AU 1631 in 
calendar year 2003 had a median GS-level of 13 and had been at the 
USPTO for a median of four years.114 The sixteen examiners in AU 
2123 had a median GS-level of 11.5 and had been at the USPTO for a 
median of two years.115 
Finally, for reasons introduced in Part II.C and discussed further 
below, the particular legal details of examination may have been quite 
technology-specific. This was true not only because of practical dif-
ferences in the definition of a PHOSITA116 and the relative unpredict-
ability of the art,117 but also because of mechanisms by which USPTO 
guidelines and Federal Circuit case law, particularly in 2003, may 
have applied differentially to bioinformatics and “ordinary” soft-
ware.118 
In all, we were interested both in potentially divergent character-
istics of applications as they entered the two art units, and divergent 
treatment that awaited them there. As to the latter question, even as-
suming comparable inputs, the literature led us to form several hy-
potheses about differential examination. 
B. Hypotheses About Examination 
First, we expected significant differences in treatment under the 
written description requirement of 35 U.S.C. § 112(a). Not long after 
the creation of AU 1631, the USPTO in early 2001 finalized its 
Guidelines for Examination of Patent Applications Under the 35 
U.S.C. § 112 ¶ 1, “Written Description” Requirement.119 Although 
the guidelines did not, on their face, apply only to biotechnology, all 
of their examples came from biotechnology, and most of the relevant 
                                                                                                                  
113. Id. 
114. FOIA-Requested USPTO Personnel Data (on file with author Arti K. Rai). 
115. Id. 
116. See supra notes 45–50. 
117. In re Fisher, 427 F.2d 833, 839 (C.C.P.A. 1970) (explaining that the scope of ac-
ceptable instruction in the patent varies inversely with the level of scientific or technological 
unpredictability that is involved). 
118. Supra notes 46–49 and accompanying text (discussing divergent standards of suffi-
ciency as to patentability based on the unpredictability of the field). 
119. 66 Fed. Reg. 1099 (Jan. 5, 2001). 
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Federal Circuit case law at the time addressed biotechnology.120 Thus, 
we expected more stringent application of the written description re-
quirement to applications assigned to AU 1631. We further hypothe-
sized that examiners would find it difficult to confine written 
description rejection to the strictly biological aspects of applications, 
and thus this stringent application would “spill over” into the “soft-
ware” aspects of the invention — the net result being that applications 
would sometimes be rejected for failing to fully describe relevant al-
gorithms and data. 
Notably, we expected stricter application of the written descrip-
tion requirement, even though the literature on examiner characteris-
tics discussed in Part III might lead us to believe that the higher GS-
level examiners in AU 1631 would be less likely to administer a thor-
ough examination. Our prediction was that higher education levels 
and clear expectations that written description should apply strictly to 
applications involving biotechnology would counteract any effects 
arising from examiner GS-level.  
Second, we wanted to examine any differences in other aspects of 
the patent law that implicate notice — specifically: definiteness, dou-
ble patenting, and restriction requirements. Here, we did not have a 
specific hypothesis but were motivated by the persistent criticism that 
software patents fail in their notice function. 
Third, we expected examination in AU 1631 to more strictly ap-
ply the utility requirement of 35 U.S.C. § 101. At the same time it 
issued its Written Description Guidelines, the USPTO issued its Utili-
ty Examination Guidelines.121 Although these guidelines were nomi-
nally agnostic as to technology, they were written with biotechnology 
in mind.122 Thus, we expected more stringent application of the utility 
requirement to applications that claimed biotechnology-related inven-
tions. Again, our prediction was that higher education levels and clear 
expectations of how to examine applications touching on biotechnol-
ogy would counteract any effects arising from GS-level. 
Fourth, we expected differences in treatment under both the ena-
blement requirement of 35 U.S.C. § 112(a) and the nonobviousness 
requirement of 35 U.S.C. § 103. With respect to enablement, we pre-
dicted that the greater unpredictability of biotechnological arts and the 
impact of such unpredictability on what a person of ordinary skill in 
the art would consider enabled would lead to a higher rejection rate. 
Again, our prediction was that higher education levels and clear ex-
                                                                                                                  
120. See Arti K. Rai, Patent Validity Across the Executive Branch: Ex Ante Foundations 
for Policy Development, 61 DUKE L.J. 1237 (2012) (discussing the tortured history of the 
written description and utility guidelines). 
121. 66 Fed. Reg. 1092 (Jan. 5, 2001). 
122. See Rai, supra note 120. 
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pectations of how to examine applications touching on biotechnology 
would counteract any effects of GS-level. 
As for nonobviousness, we expected that the strict requirement 
that existed prior to 2007 for an examiner to identify teaching, sugges-
tion, or motivation in order to combine prior art123 would lead to a 
lower nonobviousness rejection rate for bioinformatics because of its 
interdisciplinary nature. This effect would arise on top of any differ-
ence in nonobviousness rejection rate caused by unpredictability in 
the field. In this case, GS-level effects might be a third factor leading 
to lower rates of nonobviousness rejection. 
C. Results: Applications 
To test our hypotheses and describe more fully the contours of 
USPTO bioinformatics examination early in its history, we reviewed 
by hand the prosecution histories of patent examinations that were 
filed between January 1 and December 31, 2003, and were assigned to 
AU 1631 or AU 2123. These examination records are publicly availa-
ble from the USPTO Patent Application Information Retrieval (PAIR) 
system124 as well as in bulk through Google125 and, more recently, 
Reed Tech.126 
We chose calendar year 2003 because it represented the first year 
for which full prosecution history data on all applications were avail-
able on PAIR. Additionally, by 2003, AU 1631 had become reasona-
bly well-established. However, at the same time, the application of 
software to biology was not yet considered entirely routine. Thus, for 
example, in 2003, bioinformatician Lincoln Stein famously gave bio-
informatics “ten years to live,”127 predicting that although informatics 
would continue to expand and be used, it would, within ten years, be 
absorbed into biology.128 
For each prosecution, we collected information on patent applica-
tion characteristics, which, as the empirical literature discussed in Part 
III suggests, bears on one or more of the following: (1) scientific im-
portance; (2) private value; and (3) legal validity. Specifically, we 
                                                                                                                  
123. This requirement was relaxed in KSR Int’l Co. v. Teleflex Inc. 550 U.S. 398, 401 
(2007). 
124. Patent Application Information Retrieval, USPTO, 
http://portal.uspto.gov/pair/PublicPair (last visited Dec. 17, 2015). 
125. USPTO Bulk Downloads: Patents, GOOGLE, 
http://www.google.com/googlebooks/uspto-patents.html [http://perma.cc/G6E2-KRP4]. 
126. USPTO Data Sets, REED TECH. & SVCS. INC., http://patents.reedtech.com/patent-
products.php [http://perma.cc/HS33-MAEL]. 
127. Daniel H. Steinberg, Stein Gives Bioinformatics Ten Years to Live, O’REILLY 
MEDIA (Feb. 5, 2003), http://archive.oreilly.com/pub/a/network/biocon2003/stein.html 
[http://perma.cc/N397-DFWW]. 
128. Id. 
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collected information on: (1) number of inventors (scientific im-
portance); (2) number of claims; (3) family size; and (4) application 
and/or grant in the European Patent Office (“EPO”) and Japan Patent 
Office (“JPO”) (private value) and applicant-cited prior art, including 
Non-Patent Literature (“NPL”) (legal validity). 
In total, we gathered data on 565 prosecution histories, 393 from 
AU 1631 and 172 from AU 2123. Univariate analysis was performed 
using unpaired two-tailed t-test for continuous variables and Fisher’s 
exact test for categorical variables. Significance was assessed using an 
alpha of 0.05. Table 2 illustrates the differences in these measures 
among applications in both art units. Virtually all the differences are 
statistically significant at the mean, as Table 2 shows. 
Table 2: Two-Tailed Comparison of Means for Application and 
Examination Process Characteristics 
Characteristic Mean (AU 1631) 
Mean 
(AU 2123) 
Inventors *** 3.36 2.31 
Claims *** 38.41 26.15 
Applicant Cited Prior Art *** 30.17 8.72 
Applicant Cited NPL *** 20.97 4.41 
Family Size *** 3.05 2.26 
Applied in EPO *** 0.48 0.26 
Granted in EPO * 0.12 0.06 
Applied in JPO  0.35 0.30 
Granted in JPO * 0.09 0.17 
Family Size *** 3.05 2.26 
*p < 0.05; **p < 0.01; ***p < 0.001 
 
Thus, notwithstanding the fact that both sets of applications in-
volved software used for modeling and simulation, applications in AU 
1631 were more scientifically important (number of inventors), pri-
vately valuable (numbers of claims, family size, and application in the 
EPO and JPO), and likely to be legally valid (applicant cited prior art, 
including NPL), than applications in AU 2123.  
To some extent, our results on incoming patent applications are in 
line with, and reinforce, the theme of quality variation across patent-
ing in different technologies that we discussed in Parts II.C and III.C. 
That said, the fact that such variation occurs even when the actual 
scientific difference between the technologies in question (software 
for biological modeling vs. general modeling software) is quite mod-
est is striking.  
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D. Results: Examination 
Although the disparity in application characteristics was not 
unexpected, it did indicate to us that we needed to create a new data 
set for purposes of testing examination results. Specifically, we decid-
ed to create a subset that consisted of a matched sample of applica-
tions in the two art units. We matched applications on the following 
variables: 
• Number of inventors at filing; 
• Number of claims at filing; 
• Number of applicant-cited prior art references; 
• Number of applicant-cited non-patent literature 
references; 
• Patent family size; 
• Whether concurrent application in the EPO was 
sought; 
• Whether concurrent application in the EPO was 
granted; 
• Whether concurrent application in the JPO was 
sought; and 
• Whether concurrent application in the JPO was 
granted. 
As to the latter four variables (pertaining to concurrent applica-
tions), pairs were matched directly. That is, an application from AU 
1631 was required to have the same value (true vs. false) as the poten-
tial paired application from AU 2123. For the former five variables, 
pairs were quartile-matched. For example, an application from AU 
1631 may have been in the first quartile of the distribution of number 
of inventors at filing for all AU 1631 applications. Such an applica-
tion could be paired only with an application from AU 2123 that was 
also in the first quartile of the distribution of number of inventors at 
filing for all AU 2123 applications. Where multiple potential pairs 
existed that satisfied all matching criteria, pairs were assigned ran-
domly.129 This matched sample consisted of sixty-one applications in 
each art unit. The relatively small size of this matched sample may 
cause certain examination disparities between the samples to fail to 
reach statistical significance. Thus, to the extent we discuss only dis-
parities that have statistical significance, we probably underestimate 
disparities. 
                                                                                                                  
129. We built the sets of potential pairs by hand in Excel and used that software’s ran-
dom number generator to assign pairs randomly. 
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With respect to the substance of examination, we collected infor-
mation on the statutory grounds for rejections, the source of the prior 
art that the examiner cited in support of such rejections, and the exam-
iner’s imposition of a restriction requirement, if any, through the first 
round of examination.130 Tables 3 and 4 illustrate our findings.  
As these Tables show, examination in the two art units differed 
quite significantly. We discuss these differences in detail in the next 
section. 
Table 3: Grounds for Rejection During Prosecution 
Grounds 
Proportion 
(AU 1631) 
n = 393 
Proportion 
(AU 2123) 
n = 172 
p-value 
Subject-Matter  
Eligibility 40.97% 43.02% 0.6481 
Utility 5.60% 0.58% 0.0055 
Novelty 59.29% 55.81% 0.4411 
Nonobviousness 52.67% 80.81% 0.0000 
Enablement 24.68% 8.14% 0.0000 
Definiteness 66.41% 54.65% 0.0078 
Written Description 25.19% 8.14% 0.0000 
Double Patenting 16.28% 5.81% 0.0007 
Restriction 79.90% 8.72% 0.0000 
 
Table 4: Source of Prior Art Used in Rejection131 
Source 
Proportion 
(AU 1631) 
n = 393 
Proportion 
(AU 2123) 
n = 172 
p-value 
Prior Art Cited by the 
Examiner 44.53% 66.86% 0.0000 
Prior Art Cited by the 
Applicant 7.38% 3.49% 0.0075 
Prior Art Cited by Both 17.56% 27.91% 0.0052 
 
                                                                                                                  
130. A restriction requirement is an enforcement by the examiner of the single-invention 
rule and consists of a finding by an examiner that a patent application claims “two or more 
independent and distinct inventions,” so that the applicant must restrict the application to 
one of them. 35 U.S.C. § 121 (2012). The applicant may then claim each remaining inven-
tion in a divisional application that otherwise satisfies the criteria for patentability. See 
generally 37 C.F.R. § 1.142 (2015); MPEP Ch. 0800 (9th ed. Rev. 7, Mar. 2014). 
131. The values for each art unit do not add up to 100% because there were a number of 
applications in both samples (an especially large number in AU 1631) for which prior art 
was not a basis for rejection. 
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E. Discussion 
1. Subject Matter 
The rate at which bioinformatics applications in AU 1631 re-
ceived rejections for subject matter ineligibility under § 101 (36.87%) 
was not significantly different from that of software applications in 
AU 2123 (42.62%).132 As we have discussed, given that bioinformat-
ics and other informatics bear a general taxonomic similarity and dif-
fer only in their details.133 Thus, it is perhaps unsurprising that the 
requirements of subject matter did not affect one group more than the 
other. 
That said, subject matter is a rather coarse filter for evaluating in-
ventions. Indeed, this view appears in the case law,134 the literature,135 
and even legal guidance that the USPTO has issued in response to the 
Supreme Court’s interpretation of § 101.136 For a more fine-grained 
comparison, we turn to various patentability requirements under § 112 
and § 103. 
2. Written Description: Impacts on Notice 
Supporting our first hypothesis, bioinformatics applications in 
AU 1631 did receive rejections for inadequate written description un-
der § 112 to a significantly greater extent (21.30%) than did software 
applications in AU 2123 (6.56%).137 Moreover, as we predicted, use 
of written description was not limited to the biological aspects of the 
invention; a check of the first fifteen written description rejections in 
AU 1631 for which we coded showed that thirteen of the fifteen rejec-
tions involved examiner arguments that the applicants had failed to 
describe adequately either an algorithm or relevant data.138 
                                                                                                                  
132. See supra Table 3 (finding no statistically significant difference at the 95% confi-
dence interval). Similarly, for novelty, the difference between rejections received for appli-
cations in AU 1631 (49.18%) and AU 2123 (55.74%), was not statistically significant. See 
id. 
133. See supra Part IV.A. 
134. E.g., Res. Corp. Tech., Inc. v. Microsoft Corp., 627 F.3d 859, 869 (Fed. Cir. 2010) 
(referring to § 101 as “the coarse eligibility filter”). 
135. E.g., Michael W. Carroll, One for All: The Problem of Uniformity Cost in Intellec-
tual Property Law, 55 AM. U. L. REV. 845, 892–93 (observing that “use of standards along 
the subject matter dimension permits only coarse-grained exercise of interpretive discretion 
because an adjudicator can choose only between applying all or no rights to a particular 
innovation or class of innovations”). 
136. Interim Guidance for Determining Subject Matter Eligibility for Process Claims in 
View of Bilski v. Kappos, 75 FED. REG. 43,922, 43,926 (July 27, 2010) (explaining that 
“Section 101 is merely a coarse filter”). 
137. Id. 
138. The written description rejections we examined arose in application numbers 
10/204849, 10/304496, 10/309152, 10/309391, 10/332999, 10/345905, 10/350341, 
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As previously discussed, adequate written description requires 
disclosure of structure commensurate with the scope of what is 
claimed.139 As a result, it may somewhat limit scope, perhaps unduly. 
The written description requirement’s chief virtue is its promotion of 
boundary notice. In turn, certainty about patent boundaries offers a 
number of benefits including the ability to assess the value of patent 
rights for transaction and commercialization,140 to “distinguish the 
invention or discovery from other things before known and used”141 in 
determining freedom to operate, and, most simply, to avoid infringe-
ment of a competitor’s patents.142 
Taken in historical context, this finding as to bioinformatics in-
ventions in AU 1631 and more conventional informatics inventions in 
AU 2123 suggests that the structural specificity that already existed 
for biological and biochemical inventions invited more robust exam-
iner scrutiny of the relatively unstructured software elements of appli-
cations in AU 1631. The alternative inference is that applications on 
conventional software informatics inventions in AU 2123 received 
fewer written description rejections, because they were already better 
described under § 112. This inference, however, is inconsistent with 
the widely accepted view, discussed in Part II.C, that conventional 
software patents pose substantial challenges for notice. Moreover, as 
we discuss further in Part V, current patent notice reform efforts 
aimed at improving the correlation between functional claiming and 
corresponding structure also focus heavily on software. 
3. Other Indicia of Notice 
Our results also showed differences in examination with respect 
to other indicia of patent notice. Three measures in our results — def-
initeness, double patenting, and restriction — were particularly rele-
vant in this regard. The definiteness requirement promotes boundary 
notice by requiring that patent claim terms clearly delineate ex ante 
                                                                                                                  
10352246, 10/359439, 10/360747, 10/360796, 10/363727, 10/432932, 10/430685, and 
10/378866. Of these, only two (10/304496 and 10/359439) applied written description to the 
biological aspect of the invention. 
139. See supra note 22 and accompanying text. 
140. See generally Craig Allen Nard, Certainty, Fence Building, and the Useful Arts, 74 
IND. L.J. 759 (1999). In advocating for opposition proceedings to test closely the validity of 
patents and provide early certainty, Professor Nard argues that such a proceeding “will 
facilitate greater accuracy in private valuation because, as the prior art picture becomes 
more complete during prosecution, the more informed the parties will be with respect to the 
boundaries of the claimed invention.” Id. at 765–66. 
141. Nautilus, Inc. v. Biosig Instruments, Inc., 134 S. Ct. 2120, 2124–25 (2014) (citing 
the first Patent Act, Act of Apr. 10, 1790, § 2, 1 Stat. 110; the Act’s call for definiteness in 
claims continues to animate patent law to the present day). 
142. See Halliburton Energy Servs., Inc. v. M-I LLC, 514 F.3d 1244, 1249 (Fed. Cir. 
2008); Laitram Corp. v. Cambridge Wire Cloth Co., 863 F.2d 855, 856–57 (Fed. Cir. 1988). 
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the metes and bounds of an invention as claimed in the patent.143 The 
double patenting rule furthers this goal by exerting downward pres-
sure on the sheer quantity of rights that a market actor must navigate 
and clear, particularly because the existence of duplicative patent 
rights injures the public’s expectation that the expiration of a patent 
on an invention will leave that invention free for public use.144 This 
rule recognizes that even if individual patent rights were perfectly 
clear ex ante — an assumption that is far from realistic — the discov-
ery costs of identifying relevant rights145 are also a function of scale. 
Put another way, if the capacity to search effectively does not survive 
increasing size and complexity in the set of all patent rights, then 
search bottlenecks may still cause notice failures.146 
Unlike definiteness and double patenting, which clearly promote 
notice, the single invention rule has more complex effects. On the one 
hand, it furthers notice by mitigating the complexity of patent rights in 
somewhat the same way that the definiteness requirement seeks to do. 
Whereas definiteness offers clarity in evaluating claims within a pa-
tent, restriction offers clarity in evaluating inventions within a patent. 
Examiners commonly impose restriction requirements in pharmaceu-
tical-and biotechnology-related applications because it is common for 
applications in those fields to claim numerous related chemical com-
pounds or processes that turn out to be patentably distinct.147 
That said, there is evidence that divisional applications occur not 
only among the least valuable patents, where applicant ignorance 
might be the cause, but also among the most valuable patents, sug-
gesting that sophisticated applicants sometimes draft claims calculated 
to provoke restriction by the examiner.148 This evidence may mean 
that applicants who draft claims calculated to provoke restriction 
sometimes intend to produce strategic delay in examination, and that 
                                                                                                                  
143. See All Dental Prodx, LLC v. Advantage Dental Prods., Inc., 309 F.3d 774, 779–80 
(Fed. Cir. 2002) (citing Warner-Jenkinson Co. v. Hilton Davis Chem. Co., 520 U.S. 17, 28–
29 (1997)). 
144. In re Longi, 759 F.2d 887, 892–93 (Fed. Cir. 1985) (explaining that “[t]he public 
should . . . be able to act on the assumption that upon the expiration of the patent it will be 
free to use not only the invention claimed in the patent but also [obvious] modifications or 
variants”). 
145. Discovery costs are one subset of the general transaction costs that Ronald Coase 
distinguished in his theory of externalities. See R. H. Coase, The Problem of Social Cost, 3 
J.L. & ECON. 1, 15 (1960). 
146. For a systematic overview of this principle, see generally Christina Mulligan & 
Timothy B. Lee, Scaling the Patent System, 68 N.Y.U. ANN. SURV. AM. L. 289 (2012). 
147. Matt Browning, Now You See Them, Now You Don’t: The USPTO’s Rules on 
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this practice is particularly common in biotechnology.149 If so, re-
striction may actually hinder public notice by creating market uncer-
tainty about whether later-issued patent rights may encumber sunk 
investments.150 In any case, the paradox of the restriction require-
ment’s notice benefit is that, by carving up multi-invention applica-
tions into patentably distinct sets of rights, the single invention rule 
actually increases the total set of rights to be searched and cleared,151 
but it does so by reducing the patent-to-invention relationship to a 
simple one-to-one correspondence.152 
 With respect to all three rejection grounds in our matched sample, 
the percentage of rejections in AU 1631 was higher. And on two of 
the three rejection grounds, the difference was statistically significant 
at the power of the study. With respect to indefiniteness, applications 
in AU 1631 received more rejections (62.30%) than did applications 
in AU 2123 (40.98%).153 Second, with respect to the double-patenting 
rule, applications in AU 1631 received more than twice as many re-
jections (13.11%) than did applications in AU 2123 (4.92%),154 alt-
hough this second result was not statistically significant at the power 
of this study. Third, with respect to the single invention requirement 
of § 121 to manage the complexity of patent rights by limiting each 
patent to one invention,155 applications in AU 1631 received an order 
of magnitude more rejections (70.49%) than did applications in AU 
2123 (6.56%).156 
Unlike with written description, no specific USPTO guidance in-
structed examiners in AU 1631 to apply these other notice require-
ments vigorously. The reason for generally higher levels of rejection 
in AU 1631 is therefore not clear. It is possible that higher educational 
levels could have led examiners in AU 1631 to police notice more 
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vigilantly, despite the fact that examiners in AU 1631 were more 
time-constrained on average than examiners in AU 2123.157  
Supporting our third hypothesis, bioinformatics applications in 
AU 1631 received rejections for inadequate utility under § 101 much 
more frequently (8.20%) than the traditional software informatics ap-
plications in AU 2123 (0.00%).158 Possibly the Utility Guidelines that 
the USPTO issued in 2001, requiring a specific assertion by the appli-
cant of the utility of the claimed invention,159 had some effect on ex-
aminers. 
4. Enablement and Nonobviousness 
The results did not support our hypothesis that bioinformatics ap-
plications in AU 1631 would receive significantly more rejections for 
inadequate enablement under § 112 (a) than would traditional soft-
ware informatics applications in AU 2123.160 Arguably, the most no-
table feature of the enablement results was the low frequency of these 
rejections across both art units. This low frequency is consistent with 
the view that enablement rejections are complex, fact-and prior art-
intensive inquiries that time-and resource-constrained examiners are 
unlikely to favor. 
Consistent with our hypothesis, applications in AU 2123 did re-
ceive significantly more rejections for obviousness (78.69%) than did 
applications in AU 1631 (39.34%).161 In general, across all three 
hundred ninety-nine AU 1631 prosecution histories that we analyzed, 
examiners conducted prior art searches in both biology and software 
in the majority of cases. However, given that bioinformatics was still 
an emerging interdisciplinary field as of 2003, and given that the rele-
vant pre-KSR law at the time required a very specific teaching, sug-
gestion, or motivation in the art in order to combine prior art 
references, examiners were apparently quite reluctant to combine life 
science and software prior art. This reluctance appeared even though 
the applications in question, which had an average of 3.36 inven-
tors,162 presumably often included both inventors with biological and 
software skills. 
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In Part V, we discuss further the policy implications of our find-
ings for patent quality. We also discuss the normative question of how, 
in view of these empirical findings, patent applications on interdisci-
plinary, team-based inventions should be examined. We propose that 
the answer turns in part on when the interdisciplinarity of the field in 
question itself becomes relatively routine. In the case of bioinformat-
ics, this may have occurred before 2003. However, given the Federal 
Circuit’s pre-KSR demand of a written teaching, suggestion, or moti-
vation requirement, examiners may have been reluctant to combine 
life science and software references. 
V. POLICY IMPLICATIONS FOR PATENT QUALITY AND 
TEAM-BASED INNOVATION 
Given our relatively specific empirical focus on two art units, we 
tread carefully when it comes to implications for the patent system as 
a whole. However, our results do have implications for two areas: 
patent quality and examination of team-based innovation. 
A.  Patent Quality 
As for quality, our results suggest that some combination of ex-
aminer training and advanced educational background may have an 
impact on patent quality, particularly with respect to notice. Thus, 
efforts to train examiners, particularly in the use of the written de-
scription requirement, and in mechanisms by which patent applicants 
can be forced to specify the meaning of potentially problematic claim 
terms,163 are likely to prove fruitful. Moreover, while the USPTO is 
unlikely to attract significant numbers of individuals with advanced 
degrees in most art units, training examiners in basic principles of 
scientific peer review may prove useful as well. 
B. Team-Based Innovation 
Our inquiry also has implications for patent examination in an era 
of team-based, interdisciplinary science. Scientific knowledge produc-
tion is increasingly team-based; indeed team sizes have risen at an 
average rate of 15% to 20% per decade, and this increase appears in 
nearly all subfields of research and invention.164 Patent applications 
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have mirrored this shift. All areas of patenting have increased in team 
size over the past 25 years across all countries.165  
The recognition that knowledge production is increasingly team-
based has prompted some scholars to call for a doctrinal shift away 
from the familiar legal reference point of a “person having ordinary 
skill in the art” (“POSITA”) to a “team having ordinary skill in the art” 
(“TOSITA”). In a 2002 article, for example, Joseph Meara suggested 
that in fields where advances are typically made in interdisciplinary 
teams, a team-based standard would be more appropriate than an indi-
vidual standard.166 Meara gave the example of implementing a Dutch 
auction on the Internet. In that example, a team consisting of a soft-
ware engineer and a businessperson with MBA training would pre-
sumably have found the idea obvious, even though either individual 
alone might not have. 
Although Meara’s proposal was promulgated prior to KSR v. Te-
leflex, the principles of that proposal apply with even greater force 
after KSR. In a 2011 article advocating an inducement standard for 
nonobviousness (under which patents would be granted only on those 
inventions that “would not be disclosed or devised but for the in-
ducement of a patent”),167 Michael Abramowicz and John Duffy en-
dorsed making the inducement determination at the level of the 
inventive team.168 
We build upon this earlier work, but propose a slightly different 
approach. In our view, a team-based approach should be used when a 
field has become routinely interdisciplinary. This is because the very 
act of creating a team may be innovative when it brings two previous-
ly disparate fields together into a new combinatorial space. Moreover, 
although a patent grant may not always be a sign of true invention (for 
the reasons we have discussed at length), at least some of these pa-
tents were presumably granted at a time when the interdisciplinarity in 
question was still nascent. 
Recent empirical work has begun to quantify this combinatorial 
process of invention. Notably, a new study of U.S. patent and tech-
nology classification records from 1790 to 2010 demonstrates that 
patenting over that time has been characterized not only (or even pri-
marily) by the creation of new technological capabilities but by the 
increasingly complex combination of existing technological building 
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blocks.169 Because the USPTO assigns relevant USPC classifications 
to each patent,170 a patent’s classes identify the distinct technologies 
that the inventor combined to produce the invention — and the com-
bination identifies the particular interdisciplinarity at work in that in-
stance of inventive activity.171 Historically, the rate at which new 
inventions have introduced new technological capabilities, represent-
ing new technological classes, has slowed considerably.172 Yet sur-
prisingly, the rate at which new combinations of technological classes 
have emerged has systematically kept pace with the number of new 
patents.173 
These results suggest that whereas some inventions represent new 
combinations of technological capabilities, other inventions represent 
merely existing combinations of technological capabilities. The for-
mer shows emerging interdisciplinarity; the latter, routine investiga-
tion within an increasingly well-defined field. A prior empirical study 
demonstrated that there is a 60% likelihood that a given invention 
augurs a new technological combination and only a 40% likelihood 
that it relies on an existing technological combination.174 Thus, inter-
disciplinarity is, and historically has been, the prevailing mode of in-
novation. 
To be sure, our proposed doctrinal inquiry of routine interdisci-
plinarity may sometimes prove difficult to implement. Beyond the 
ordinary line-drawing problems that inform all such taxonomic de-
terminations, there is the added temporal difficulty of determining 
when previously unrelated disciplines should be regarded as solidly 
linked. 
In the particular case of bioinformatics, we proceed with the ben-
efit of a historical record. The systematic collection and analysis of 
biological sequence data has commanded the collaborative efforts of 
“computer scientists, statisticians, and biologists” for over four dec-
ades,175 and the term “bioinformatics” itself dates from 1970.176 The 
idea of a bioinformatician proper, however, is of more recent vintage, 
dating between the mid-1990s177 and the early 2000s.178 During this 
                                                                                                                  
169. Hyejin Youn et al., Invention as a Combinatorial Process: Evidence from US Pa-
tents, 12 J. ROYAL SOC’Y INTERFACE 20150272, at *3 (2015), 
http://rsif.royalsocietypublishing.org/content/12/106/20150272.full-text.pdf 
[http://perma.cc/2P4M-7ERF]. 
170. See supra note 103 and accompanying text. 
171. Youn et al., supra note 169, at *3–4. 
172. Id. at *4. 
173. Id. 
174. Id. at *5. 
175. Andrew Chin, Research in the Shadow of DNA Patents, 87 J. PAT. & TRADEMARK 
OFF. SOC’Y 846, 894 (2005). 
176. Paulien Hogeweg, The Roots of Bioinformatics in Theoretical Biology, 7 PLOS 
COMPUT. BIOL. e1002021 at *1 (2011). 
177. See Contreras, supra note 6 and accompanying text. 
240  Harvard Journal of Law & Technology [Vol. 29 
 
time, public accounts began referring to bioinformatics as its own 
field.179 Moreover, universities, such as the University of Michigan180 
and the University of California San Diego,181 began establishing 
training and degree programs in bioinformatics.182 
To the extent of its authority, the USPTO worked to stay abreast 
of this shift toward team-based scientific research. The agency estab-
lished its art unit in bioinformatics precisely as the fields of biology 
and software were becoming solidly linked. Indeed, as previously not-
ed, by the year 2003 (the year that we studied), the role of computer 
science in biology was sufficiently well-established that Lincoln Stein 
predicted bioinformatics had only “ten years to live” as a field that 
could be considered interdisciplinary in the first instance.183 However, 
the shadow of the Federal Circuit’s very exacting requirements for 
combining prior art may have kept AU 1631 from fully assimilating 
team-based research norms and practices. This intuition could be test-
ed, at least to some extent, by analyzing the frequency of obviousness-
based rejections in AU 1631 after the Supreme Court decision in KSR 
v. Teleflex. 
VI. CONCLUSION 
The empirical data on bioinformatics examination that this Article 
has presented may offer important contributions to the literature on 
patent quality. We have shown that patent applications in bioinformat-
ics generally received more stringent examiner scrutiny and more re-
jections, particularly on notice-related grounds, than did applications 
in conventional software informatics. Bioinformatics examiners paid 
significant attention to notice not only in the biological aspects of the 
inventions that they examined, but also in the inventions’ strictly in-
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formational aspects. Our results suggest that institutional investment 
in human capital and educational training can make a difference.  
Our results did not hold, however, for application of the nonobvi-
ousness requirement before the KSR decision. KSR may therefore 
have been a particularly important precedent for proper evaluation of 
interdisciplinary and team-based science. 
Our Article also offers the first empirical account of patent qual-
ity at the juxtaposition of two fields generally believed to be wholly 
opposed with respect to patent quality, particularly boundary notice. 
At the stage of initial application, we found significant evidence that 
bioinformatics applications were “better” than conventional informat-
ics applications. 
Finally, our results invite further study of invention that is con-
ducted in collaborative environments and draws on expertise in a va-
riety of disciplines, as bioinformatics does. A richer empirical account 
of these inventive activities would do much to align the U.S. patent 
system with the modern realities of team-based innovation. 
